Background {#Sec1}
==========

Frailty, as a geriatric syndrome, represents a reduced ability to rebuild homeostasis in response to external stressors during daily life \[[@CR1]\]. Frailty in the elderly is well established to be related to long-term adverse health outcomes (such as falls, depression, disability, dependency, and mortality) that cannot be completely explained by ageing, functional decline, or comorbidities \[[@CR2]--[@CR5]\].

Of the numerous existing frailty measures, many often rely on measuring physical function, with some being less likely to be readily available in clinical settings and, therefore, having limited use \[[@CR6]--[@CR8]\]. Common approaches such as the Frailty Index \[[@CR9], [@CR10]\] and the Frailty Phenotype \[[@CR11]\] are no exceptions. In contrast, the Study of Osteoporotic Fractures (SOF) frailty index employs only 3 simple self-reported frailty components, muscle strength, low energy, and unintentional weight loss \[[@CR7]\]. Frailty identified through this measure has been associated with falls, disability, fractures, and death \[[@CR6], [@CR12]\], and the SOF index is regarded as a useful tool for assessments of the physical aspects of frailty at the population level \[[@CR7], [@CR8], [@CR13]\].

Vitamin D, which is primarily synthesized in the skin upon exposure to sunlight, is necessary for human musculoskeletal health maintenance \[[@CR14]\]; its deficiency is proven to be the cause of muscle weakness \[[@CR15]\], sarcopenia \[[@CR16]\], falls \[[@CR17]\], and fracture \[[@CR18]\]. A growing body of evidence has suggested that a low level of its active form, namely, 25-hydroxyvitamin D \[25(OH)D\], is related to the risk of frailty \[[@CR19]--[@CR33]\]. The underlying pathogenic mechanisms of this relationship could be explained through 3 pathways: the first is the invalidation of regulatory effects of vitamin D on calcium flux, mineral homeostasis and protein anabolism in muscle tissue \[[@CR23], [@CR24]\]; the second is bone metabolic disturbance by secondary hyperparathyroidism \[[@CR25]\]; and the last is the possible anti-inflammatory property of vitamin D \[[@CR26]\].

However, since the cutaneous synthesis of vitamin D shows great variability across populations \[[@CR34]\], studies exploring its association in elderly Asian populations are limited. Moreover, as this cutaneous synthesis process decreases with age \[[@CR35]\], and limited outdoor activities may also accelerate vitamin D deficiency \[[@CR14]\], the relationship between 25(OH) D and frailty in the oldest-old people (aged ≥80 years) remains unclear. Since the oldest-old will be the fastest-growing group between now and 2050 \[[@CR11]\], the association between 25(OH) D level and the risk of frailty in this age group may have important public health implications for health-care planning and practice.

Therefore, this study aimed to examine the association between 25(OH) D level and the risk of frailty among 1324 oldest-old adults of the eight "longevity areas" in the Chinese Longitudinal Healthy Longevity Survey (CLHLS) \[[@CR36], [@CR37]\]. Given the evidence in previous studies, we hypothesized that a lower level of 25(OH) D would be associated with the risk of frailty in Chinese community-based oldest-old people.

Methods {#Sec2}
=======

Study design and participants {#Sec3}
-----------------------------

Participants in the biomarker substudy from the 6th (2011) wave of the CLHLS were recruited in this secondary analysis. The CLHLS is the first and largest nationwide, community-based, longitudinal prospective cohort survey concerning older adults in China \[[@CR38]\]. It provides information on the health status, socio-economic characteristics, and lifestyles of elderly individuals, including a large percentage of the oldest population \[[@CR37]\]. The in-depth study was launched in eight "longevity areas" of China (Laizhou of Shandong Province, Xiayi of Henan Province, Zhongxiang of Hubei Province, Mayang of Hunan Province, Sanshui of Guangdong Province, Yongfu of Guangxi Autonomous Region, Chengmai of Hainan Province, Rudong of Jiangsu Province), where the density of centenarians was exceptionally high and the environmental quality was very good, as evaluated and officially designated by the expert committee of the Chinese Gerontology Association \[[@CR36]\].

During the in-depth study, the Chinese Center for Disease Control and Prevention (CDC) local network medical doctors conducted physical examinations of the participants and collected biomarker datasets containing approximately 30 indicators in routine blood tests, blood biochemical tests, and urine tests \[[@CR36]\]. More detailed descriptions have been previously published elsewhere \[[@CR39]--[@CR41]\].

Initially, a total of 2439 elderly participants were included in the study. We excluded those of younger age (less than 80, *n* = 834, 34.2%) and those with missing data on SOF index components (*n* = 281, 11.5%). Finally, we retained 1324 older adults in this study.

Outcome {#Sec4}
-------

Consistent with previous studies of secondary analyses involving CLHLS data \[[@CR42]\], frailty was defined by the SOF index in the current study. Three components were included in the index: underweight (defined as body mass index \< 18.5), low energy level (indicated by a positive response to the question "Over the last 6 months, have you been limited in activities because of a health problem?"), and muscle strength (inability to stand up from a chair without the assistance of arms). As suggested, participants with two or more of the three components were defined as frail.

Exposure {#Sec5}
--------

Fasting venous blood was collected after an overnight fast from all willing participants. Procedures for the collection and shipment of blood samples were described in detail elsewhere \[[@CR14]\]. 25(OH) D was assayed by an enzyme-linked immunoassay using Immunodiagnostic Systems Limited (IDS Ltd., Boldon, UK). The 25(OH) D level was expressed as nmol/L.

Covariates {#Sec6}
----------

We adjusted for socio-demographic variables, health characteristics and confounding biomarkers in the models. Socio-demographic variables included age, sex (female/male), marital status (married/other), residence (rural/other), education level (no schooling/≥1 year of schooling), and co-residence \[with family member(s)/other\].

Health characteristics included lifestyles and chronic diseases. Lifestyles consisted of smoking (yes/no), drinking (yes/no), and regular exercise (yes/no) at present. Chronic diseases included hypertension (yes/no), diabetes mellitus (yes/no), heart diseases (yes/no), cerebrovascular diseases (yes/no), and respiratory diseases (yes/no). Hypertension was defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg \[[@CR43]\]. Diabetes mellitus was diagnosed by fasting plasma glucose≥7.0 mmol/L \[[@CR14], [@CR44]\]. Other diseases were identified by self-report.

Confounding biomarkers were 11 indicators on routine blood tests and blood biochemistry tests \[[@CR36]\]. According to previous relevant studies \[[@CR19]\], these 11 indicators, which were largely investigated in relation to frailty, were analysed in this study: 1) inflammatory marker: C reactive protein (CRP); 2) immune marker: counts of leukocytes (WBC); 3) clinical markers: plasma albumin (ALB), total cholesterol (CHO), serum creatinine (CREA), high-density lipoprotein cholesterol (HDLC), low-density lipoprotein cholesterol (LDLC), triglyceride (TG), and haemoglobin (HGB); and 4) oxidative stress markers: malondialdehyde (MDA) and superoxide dismutase (SOD). All standard laboratory techniques were performed by the central clinical laboratory at Capital Medical University in Beijing.

Overall, few data points for most confounding variables were missing (1.05%). For the missing values, we performed multiple imputations by chained equations to increase the predictive power \[[@CR45]\]. The distributions of the observed data and imputed data are described in **Supplementary Table S1 (see** Additional file [1](#MOESM1){ref-type="media"}**)**. For all the covariates, the distributions of observed and imputed values were similar.

Statistical analysis {#Sec7}
--------------------

Categorical variables were expressed as numbers and percentages, and continuous data were described as the mean (standard deviation, SD) or median (interquartile range, IQR). Characteristics among groups were compared by ANOVA, Kruskal--Wallis test or χ^2^ test. The IQR of the 25(OH) D level was used to divide the data into four categories. The cutoff points were 26.13, 35.89, and 50.00 nmol/L.

We used multilayer logistic regression models based on the likelihood ratio test (LRT) to determine the association between 25(OH) D level and the risk of frailty. The Box-Tidwell method was used to test the linearity between logit P and all continuous variables \[[@CR46]\]. Therefore, we used continuous terms for all the confounding biomarkers and categorized age as subgroups with 80--89, 90--99, and ≥ 100 years. Data are reported as odds ratios (ORs) and 95% confidence intervals (CIs) in both unadjusted and adjusted logistic regression models. A *p*-value of the Hosmer-Lemeshow test \> 0.05 indicated reasonable goodness of fit \[[@CR47]\].

Different from previous studies, to examine the linear trend across levels of 25(OH) D, we further performed spline smoothing analysis and threshold effect analysis in the current study, which were relatively novel in studies examining the respondents' dose-response relationship between 25(OH) D and frailty. Instead of a priori assumptions, spline smoothing analysis is a form of mixed modelling based on the generalized additive model (GAM) \[[@CR48]\], whereby a set of associated items, for example, 25(OH) D and frailty, can visually demonstrate the linear or curvilinear relationship by figures. The threshold effect analysis, which is based on the piece-wise regression model \[[@CR49]\], can further examine whether this relationship is segmental.

Subgroup analyses and their interactions were tested to explore whether sex and age subgroups would confound the association between 25(OH) D level and frailly. Sensitivity analysis was performed in participants with complete variables and multiple imputations separately.

A two-tailed *p*-value \< 0.05 was considered statistically significant in all analyses. Statistical analyses were conducted by IBM SPSS Statistics Version 22.0, except that the spline smoothing analysis, threshold effect analysis, and multiple imputations were performed by R software Version 3.4.3 ([http://www.R-project.org](http://www.r-project.org)) and Empower® ([www.empowerstats.com](http://www.empowerstats.com)).

Results {#Sec8}
=======

Sample characteristics {#Sec9}
----------------------

The characteristics of the participants were compared according to the 25(OH) D level categories. The full detailed characteristics of all participants are shown in Table [1](#Tab1){ref-type="table"}. The mean ± SD age of the study population was 92.89 ± 7.92 years, and 63.7% were women (*n* = 844). The number of participants with frailty was 426 (33.2, 95% CI: 29.66--34.69). The median 25(OH) D concentration was 35.89 nmol/L, and participants with higher 25(OH) D levels (35.89--50.00, \> 50.00 nmol/L) were significantly younger than those with lower levels (≤26.13, 26.13--35.89 nmol/L) and were more likely to be male, married, have ≥1 year of schooling and perform regular exercise. Table 1Participant characteristicsVariablesAll participants (*n* = 1324)Categories (nmol/L)Statistics ^a^Q~1~ (≤26.13)Q~2~ (26.13--35.89)Q~3~ (35.89--50.00)Q~4~ (\> 50.00)**Socio-demographics**, *n* (%) Age (80--112), M (SD)92.89 (7.92)95.63 (7.49)93.37 (7.72)91.85 (7.85)90.70 (7.78)25.207^\*\*\*^ Female844 (63.7)251 (75.8)236 (71.3)200 (60.2)157 (47.6)68.190^\*\*\*^ Married294 (22.3)44 (13.3)60 (18.2)83 (25.1)107 (32.7)40.503^\*\*\*^ Rural1124 (84.9)282 (85.2)282 (85.2)265 (79.8)295 (89.4)11.925^\*\*^ No schooling998 (76.4)279 (85.8)257 (78.4)242 (74.2)220 (67.1)33.410^\*\*\*^ With household member(s)950 (73.2)263 (82.2)236 (72.2)225 (69.7)226 (69.1)25.873^\*\*\*^**Health characteristics**, *n* (%) Smoking148 (11.3)28 (8.5)39 (11.8)37 (11.2)44 (13.5)4.337 Drinking167 (12.7)32 (9.7)41 (12.5)45 (13.6)49 (14.9)0.218 Regular exercise178 (13.9)27 (8.4)38 (11.9)54 (16.7)59 (18.6)17.317^\*\*\*^ Hypertension785 (62.2)197 (61.9)195 (62.1)192 (61.5)201 (63.0)0.155 Diabetes mellitus98 (7.4)28 (8.5)25 (7.6)24 (7.3)21 (6.4)1.057 Heart diseases91 (7.0)24 (7.4)24 (7.4)27 (8.4)16 (4.9)3.398 Cerebrovascular diseases102 (7.8)34 (10.4)31 (9.5)18 (5.5)19 (5.8)8.630^\*^ Respiratory diseases116 (8.9)29 (9.0)32 (9.8)23 (7.0)32 (9.8)2.080**Biomarkers**, M (IQR) CRP (mg/L)1.01 (0.41,2.93)1.12 (0.38,3.35)0.93 (0.43,3.05)0.96 (0.41,2.54)1.09 (0.39,2.75)1.491 ALB (g/L)39.10 (35.90,42.40)37.90 (35.30,41.40)38.60 (35.48,42.12)39.70 (36.70,42.93)39.90 (37.20,42.80)29.923^\*\*\*^ CHO (mmol/L)4.16 (3.52,4.79)4.03 (3.49,4.72)4.21 (3.51,4.79)4.21 (3.47,4.97)4.20 (3.70,4.78)4.186 CREA (mmol/L)78 (65,96)69 (60,85)77 (63,93)82 (69,98)87 (71,102)76.765^\*\*\*^ HDLC (mmol/L)1.23 (1.03,1.49)1.20 (1.01,1.45)1.25 (1.04,1.51)1.27 (1.03,1.55)1.23 (1.04,1.46)5.065 LDLC (mmol/L)2.45 (1.94,3.02)2.40 (1.92,2.97)2.42 (1.89,3.05)2.41 (1.86,3.08)2.54 (2.04,3.00)5.147 TG (mmol/L)0.79 (0.59,1.10)0.78 (0.59,1.07)0.79 (0.58,1.09)0.82 (0.61,1.16)0.77 (0.57,1.07)6.429 SOD (IU/mL)58.53 (53.43,63.24)56.75 (51.75,62.97)58.18 (53.49,63.20)58.75 (53.33,63.06)59.39 (55.39,64.24)18.975^\*\*\*^ MDA (μmol/L)4.71 (3.73,5.79)4.81 (3.93,5.89)4.87 (3.88,5.91)4.84 (3.82,5.83)4.33 (3.25,5.55)27.303^\*\*\*^ WBC (10^9^/L)5.30 (4.30,6.40)4.80 (4.00,6.00)5.10 (4.10,6.10)5.60 (4.57,6.60)5.60 (5.60,6.80)34.983^\*\*\*^ HGB (g/L)118 (106,131)121 (110,133)120 (107,132)116 (105,129)117 (105,131)11.618^\*\*\*^**Frailty**, *n* (%)426 (33.2)162 (48.9)112 (33.8)93 (28.0)59 (17.9)76.606^\*\*\*^*M (SD)* mean (standard deviation), *M (IQR)* median (interquartile range)^a^ Coefficient of ANOVA, Kruskal--Wallis test or χ^2^ test among categories of plasma 25(OH) D level^\*^ \< 0.05, ^\*\*^ \< 0.01, ^\*\*\*^ \< 0.001Abbreviations: *CRP* C reactive protein, *ALB* plasma albumin, *CHO* total cholesterol, *CREA* plasma creatine, *HDLC* high-density lipoprotein cholesterol, *LDLC* low-density lipoprotein cholesterol, *SOD* superoxide dismutase, *TG* triglyceride, *SOD* superoxide dismutase, *MDA* malondialdehyde, *WBC* white blood cell count, *HGB* haemoglobin

Association between the level of 25(OH) D and the risk of frailty {#Sec10}
-----------------------------------------------------------------

As shown in Table [1](#Tab1){ref-type="table"}, 48.9%, 33.8%, 28.0% and 17.9% of participants in the lowest to highest 25(OH) D categories reported frailty. There was a significant inverse association between categorical 25(OH) D level and the risk of frailty in the multivariate logistic regression models. The ORs and 95% CIs for the association between categories of 25(OH) D level and frailty are presented in Table [2](#Tab2){ref-type="table"}. After eliminating the interferences of all confounding factors, the ORs of frailty were 3.239 (95% CI: 2.113--4.967, *p* \< 0.001) for the lowest category (≤26.13 nmol/L) of 25(OH) D level, 2.341 (95% CI: 1.519--3.609, *p* \< 0.001) for the second-lowest category (26.13--35.89 nmol/L), and 1.703 (95% CI: 1.088--2.664, *p* = 0.20) for the third-lowest category (30.33--44.46 nmol/L) compared to the highest level subgroup (\> 50.00 nmol/L). Table 2The associations between serum level of 25(OH) D (nmol/L) and the risk of frailtyVariablesModel 1 ^a^Model 2 ^b^Model 3 ^c^Model 4 ^d,\ e^Categories  ≤ 26.134.964 (3.332,7.396) ^\*\*\*^3.472 (2.273,5.303) ^\*\*\*^3.437 (2.248,5.255) ^\*\*\*^3.239 (2.113,4.967) ^\*\*\*^ 26.13--35.892.822 (1.881,4.234) ^\*\*\*^2.414 (1.571,3.710) ^\*\*\*^2.420 (1.573,3.723) ^\*\*\*^2.341 (1.519,3.609) ^\*\*\*^ 35.89--50.001.835 (1.204,2.797) ^\*\*^1.526 (1.102, 2.683) ^\*^1.722 (1.102,2.692) ^\*^1.703 (1.088,2.664) ^\*^  \> 50.00referencereferencereferencereference^a^ Unadjusted model, OR (95% CI)^b^ Adjusted for **socio-demographics** (age, sex, marital status, residence, education level, and co-residence), OR (95% CI)^c^ Adjusted for **socio-demographics** (age, sex, marital status, residence, education level, and co-residence) and **health characteristics** (smoking, drinking, regular exercise, hypertension, diabetes mellitus, heart diseases, cerebrovascular diseases, and respiratory diseases), OR (95% CI)^d^ Adjusted for **socio-demographics** (age, sex, marital status, residence, education level, and co-residence), **health characteristics** (smoking, drinking, regular exercise, hypertension, diabetes mellitus, heart diseases, cerebrovascular diseases, and respiratory diseases) and **confounding biomarkers** (CRP, ALB, CHO, CREA, HDLC, LDLC, TG, SOD, MDA, WBC, and HGB), OR (95% CI)^e^*p*-value for the Hosmer-Lemeshow test was 0.653; prediction in accuracy was 74.3% in model 4^\*^ \< 0.05, ^\*\*^ \< 0.01, ^\*\*\*^ \< 0.001

The dose-response relationship between the level of 25(OH) D and the risk of frailty {#Sec11}
------------------------------------------------------------------------------------

Consistent with the results displayed in Table [2](#Tab2){ref-type="table"}, a continuous negative curve was observed between 25(OH) D and the risk of frailty in the analysis using spline smoothing (*p* for trend \< 0.001, Fig. [1](#Fig1){ref-type="fig"}). Table [3](#Tab3){ref-type="table"} shows that the *p*-value of the log-likelihood ratio test in the threshold effect analysis was 0.317 in the adjusted model, which showed that the tendency of the association between 25(OH) D and frailty was monotonical with no inflection. Fig. 1The dose-response relationship of 25(OH) D level and the risk of frailty adjusted for socio-demographics (age, sex, marital status, residence, education level, and co-residence), health characteristics (smoking, drinking, regular exercise, hypertension, diabetes mellitus, heart diseases, cerebrovascular diseases, and respiratory diseases) and confounding biomarkers (CRP, ALB, CHO, CREA, HDLC, LDLC, TG, SOD, MDA, WBC, and HGB). Lines = estimated probability of frailty with 25(OH) D, dotted lines = 95% confidence intervalsTable 3Threshold effect analysis of 25(OH) D (nmol/L) using the piece-wise regression modelVariablesCrude ^a^\
OR (95% CI)Adjusted ^b^\
OR (95% CI)Continuous0.967 (0.960, 0.975) ^\*\*\*^0.975 (0.965, 0.984) ^\*\*\*^Cutoff  ≤ 33.960.948 (0.929, 0.967) ^\*\*\*^0.963 (0.939, 0.988) ^\*\*\*^  \> 33.960.978 (0.966, 0.989) ^\*\*\*^0.981 (0.966, 0.996) ^\*^*p*-value of log-likelihood ratio test0.0320.317^a^ Crude: no adjustment^b^ Adjusted for **socio-demographics** (age, sex, marital status, residence, education level, and co-residence), **health characteristics** (smoking, drinking, and regular exercise, hypertension, diabetes mellitus, heart diseases, cerebrovascular diseases, and respiratory diseases) and **confounding biomarkers** (CRP, ALB, CHO, CREA, HDLC, LDLC, TG, SOD, MDA, WBC, and HGB)^\*^ \< 0.05, ^\*\*^ \< 0.01, ^\*\*\*^ \< 0.001

Subgroup analyses {#Sec12}
-----------------

Subgroup analyses showed that the *p*-value for interaction was 0.9753 for sex and 0.1077 for age, which revealed that the association of 25(OH) D level with frailty did not significantly differ by sex or age after adjusting for a series of covariates (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Subgroup analyses for the association between 25(OH) D and frailty adjusted for marital status, residence, education level, and co-residence; smoking, drinking, and regular exercise; hypertension, diabetes mellitus, heart diseases, cerebrovascular diseases, and respiratory diseases; and CRP, ALB, CHO, CREA, HDLC, LDLC, TG, SOD, MDA, WBC, and HGB

Sensitivity analysis {#Sec13}
--------------------

We performed the multivariate analysis in those participants with complete variables and multiple imputations separately. As displayed in **Supplementary Table S2 (see** Additional file [1](#MOESM1){ref-type="media"}**)**, the present findings showed similar results.

Discussion {#Sec14}
==========

In this community-based study, after adjustment for a variety of potential confounding factors, we observed a robust and monotonically negative association of 25(OH) D with frailty among a group of oldest-old individuals in China. In addition, by examining the relationship between different subgroups of participants, we also indicated that this association was consistent across sex and age groups.

Comparison with other studies {#Sec15}
-----------------------------

The relationship between 25(OH) D level and frailty has rarely been investigated among the oldest-old individuals. As hypothesized, the present findings suggested that the 25(OH) D level was related to frailty after adjustment for numerous confounders. The findings from our study were relatively consistent with those of previous studies involving older adults in the Netherlands \[[@CR25], [@CR32]\], Mexico \[[@CR23]\], northern Taiwan \[[@CR33]\] and Germany \[[@CR31]\].

Limited studies have demonstrated the shape of the association between 25(OH) D level and frailty. In a study of 1606 old men aged 73.8 ± 5.9 years in the USA, a segmented negative curvilinear association between 25(OH) D level and odds of frailty was identified \[[@CR21]\]. However, this association was not observed among 6307 old women in America \[[@CR20]\] and was replaced by a U-shaped curvilinear association. For the present study, we identified a robust and monotonically negative association between 25(OH) D and frailty in older Chinese adults.

Chronic diseases, lifestyles, and some biomarkers have been studied as potential risk factors of frailty in the existing literature \[[@CR11], [@CR19], [@CR24]\]. However, the association between 25(OH) D and frailty was not substantially confounded after adding these covariates in the models of our study. This suggested that 25(OH) D was independently associated with the risk of frailty. However, it remains inconclusive whether other possible factors not included in this study might contribute to the relationship between 25(OH) D and frailty.

Due to differences in latitudes, seasons, measurements of frailty, the adequacy of adjustment for potential confounders, and clinical heterogeneity between races and ethnicities \[[@CR34]\], some variations from previous studies were also found in this study. First, our study reported that the median 25(OH) D level of elderly individuals was 35.89 nmol/L, which was lower than the median levels of those participants in Taiwan \[[@CR33]\], the Netherlands \[[@CR25]\], and Germany \[[@CR27]\]. In addition, the prevalence of frailty was 33.2%, which was much higher than the 13% reported in Japanese elderly \[[@CR8]\] and the 17% reported in US older women \[[@CR6]\]. Since the 25(OH) D level and frailty status are closely related to ageing \[[@CR19]\], these differences could also be partly explained by the oversampling of oldest-old people in this study.

Second, the association between 25(OH) D level and frailty has been reported to be different across sex \[[@CR20], [@CR21], [@CR27], [@CR28], [@CR30]\]. A study of participants in Italy identified that vitamin D insufficiency was associated with frailty only in men \[[@CR30]\]. However, conflicting results were reported in studies involving older women in the USA \[[@CR24]\], Spain \[[@CR29]\], and Portugal \[[@CR28]\]. In this regard, our study detected that 25(OH) D level was associated with frailty regardless of sex, which was similar to the findings of the study of individuals in Germany \[[@CR27]\]. In addition, our study also indicated that this association did not differ among octogenarian, nonagenarian, and centenarian subgroups.

Strength and limitations {#Sec16}
------------------------

The strength of the current study was the large number of Chinese community-based participants with the collection of plasma blood samples during the survey. This allowed us to investigate the shape of the association between 25(OH) D level and frailty and to adjust for important potential confounding variables. To our knowledge, this was the first study that investigated the relationship between 25(OH) D level and frailty in a nationwide study of Chinese oldest-old people. The present study included a large population of older Chinese adults aged 80 years and over, which allowed robust conclusions to be drawn with respect to these participants.

This study also has certain limitations. First, a dichotomous outcome measure for frailty was used in this study; hence, the pre-frail status was not taken into account. Second, some of the clinical diseases were self-reported. For this condition, we adjusted hypertension and diabetes status by clinical data in place of self-reporting to eliminate information bias. Third, this was a descriptive cross-sectional design that did not allow us to evaluate whether a change in 25(OH) D level was a cause or a consequence of frailty.

Conclusions {#Sec17}
===========

With a population-based design, this study indicates that the 25(OH) D level is monotonically and negatively associated with frailty in the Chinese community-dwelling population. The results of the present study, along with those of other existing epidemiological studies, reinforce the importance of the investigation of the full explanation of the association between 25(OH) D and frailty. Further longitudinal studies are needed to verify our initial cross-sectional findings so that we may identify an effective intervention to stem the rapidly increasing prevalence of frailty associated with an ageing population.

Supplementary information
=========================

 {#Sec18}

**Additional file 1 Supplementary Table S1** Distribution of observed data and imputed data. **Supplementary Table S2** Sensitivity analysis of 25(OH) D (nmol/L) with risk of frailty.
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